- Home
- JANX vs MEGI Comparison
JANX vs MEGI Comparison
Compare JANX & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | MEGI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 794.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JANX | MEGI |
|---|---|---|
| Price | $15.18 | $15.16 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $50.09 | N/A |
| AVG Volume (30 Days) | ★ 929.9K | 191.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $12.85 |
| 52 Week High | $35.34 | $15.89 |
Technical Indicators
Market Signals| Indicator | JANX | MEGI |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 57.47 |
| Support Level | $13.10 | $14.12 |
| Resistance Level | $15.49 | $15.29 |
| Average True Range (ATR) | 0.57 | 0.21 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 86.29 | 77.97 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.